Karyopharm Therapeutics (NASDAQ:KPTI) – Equities research analysts at Jefferies Group lowered their Q2 2018 EPS estimates for Karyopharm Therapeutics in a research note issued to investors on Tuesday, May 15th. Jefferies Group analyst M. Raycroft now forecasts that the company will post earnings per share of ($0.77) for the quarter, down from their previous forecast of ($0.62). Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for Karyopharm Therapeutics’ Q3 2018 earnings at ($0.71) EPS, Q4 2018 earnings at ($0.78) EPS, FY2018 earnings at ($3.03) EPS, FY2019 earnings at ($2.66) EPS, FY2020 earnings at ($1.05) EPS, FY2021 earnings at ($0.74) EPS and FY2022 earnings at $0.73 EPS.

Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, January 25th. Robert W. Baird set a $22.00 target price on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 15th. HC Wainwright boosted their target price on shares of Karyopharm Therapeutics to $26.00 and gave the stock a “buy” rating in a research note on Thursday, March 15th. Canaccord Genuity boosted their target price on shares of Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, March 12th. Finally, Royal Bank of Canada reiterated a “buy” rating and set a $22.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, March 2nd. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Karyopharm Therapeutics has a consensus rating of “Buy” and a consensus target price of $21.10.

Shares of Karyopharm Therapeutics opened at $19.08 on Friday, MarketBeat.com reports. Karyopharm Therapeutics has a 12 month low of $18.33 and a 12 month high of $18.89.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, May 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.11). The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $4.59 million.

In other news, EVP Christopher Brett Primiano sold 2,500 shares of the company’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $16.03, for a total value of $40,075.00. Following the completion of the sale, the executive vice president now directly owns 4,881 shares of the company’s stock, valued at $78,242.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sharon Shacham sold 10,000 shares of the company’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $16.15, for a total transaction of $161,500.00. Following the completion of the sale, the insider now directly owns 723,510 shares of the company’s stock, valued at $11,684,686.50. The disclosure for this sale can be found here. Insiders sold 67,000 shares of company stock valued at $1,021,320 in the last 90 days. 14.71% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the company. Doheny Asset Management CA purchased a new position in Karyopharm Therapeutics during the first quarter worth about $3,073,000. Palo Alto Investors LP raised its holdings in Karyopharm Therapeutics by 3.8% during the first quarter. Palo Alto Investors LP now owns 3,679,978 shares of the company’s stock worth $49,385,000 after purchasing an additional 135,539 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Karyopharm Therapeutics by 2,536.0% during the first quarter. Cubist Systematic Strategies LLC now owns 25,385 shares of the company’s stock worth $341,000 after purchasing an additional 24,422 shares in the last quarter. venBio Select Advisor LLC purchased a new position in Karyopharm Therapeutics during the first quarter worth about $7,524,000. Finally, Barclays PLC raised its holdings in Karyopharm Therapeutics by 50.7% during the first quarter. Barclays PLC now owns 42,985 shares of the company’s stock worth $577,000 after purchasing an additional 14,459 shares in the last quarter. 62.65% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.